RE:Re: Strategic acquisitions"Of course gagnon would be on the lookout for new acquistions, like the one he did with Juvenite, took a company that had hundred of thousands in sales and ran that down to less than $30,000 in sales per year..."
Too funny. You still can't see the real significance of Juvente. Gilles has proven up a number of use-cases for PGX from an immune booster, to a CoQ10 functional drink, to PGX-Fibrosis, to PGX-wound healing, to PGX-Juvente, etc.
PGX-Juvente/CoQ10 even won an industry award for "Most Innovative Raw Material" at the Cosmetic 360 Awards in Paris, France. PGX is expected to reach the decision-point for mass industrialization this quarter with PGX scale-up. Gilles has said that Symrise appreciates what they are doing with PGX and could even be a partner in the future with PGX-CoQ10 as a second-generation Aveeno. Gilles has proven PGX-CoQ10 to the point of an industry award as he looks for a partner. Gilles is also most interested in Juvente-PGX applications that will require a prescription and has looked at one application for skin cancer.
The company has also been doing wound healing studies with the Angiogenesis Foundation which could support new claims for Juvente as for wound healing.
With a number of different products about to reach commercialization from a PGX immune booster, to the beta glucan chewy product, to potentially PGX-Juvente the company may also have a portfolio of or a critical mass of products to support a sales force of its own. We will see what their strategy is with events.